10.54
2.77%
-0.30
Roivant Sciences Ltd stock is currently priced at $10.54, with a 24-hour trading volume of 64.41M.
It has seen a -2.77% decreased in the last 24 hours and a -9.99% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $10.84 pivot point. If it approaches the $10.50 support level, significant changes may occur.
Roivant Sciences Ltd Stock (ROIV) Financials Data
Roivant Sciences Ltd (ROIV) Revenue 2023
ROIV reported a revenue (TTM) of $123.24 million for the quarter ending December 31, 2023, a +185.76% rise year-over-year.
Roivant Sciences Ltd (ROIV) Net Income 2023
ROIV net income (TTM) was $4.47 billion for the quarter ending December 31, 2023, a +458.61% increase year-over-year.
Roivant Sciences Ltd (ROIV) Cash Flow 2023
ROIV recorded a free cash flow (TTM) of -$838.55 million for the quarter ending December 31, 2023, a -1.14% decrease year-over-year.
Roivant Sciences Ltd (ROIV) Earnings per Share 2023
ROIV earnings per share (TTM) was $5.20 for the quarter ending December 31, 2023, a +392.13% growth year-over-year.
Roivant Sciences Ltd Stock (ROIV) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Venker Eric | President & COO |
Feb 09 '24 |
Option Exercise |
3.85 |
96,950 |
373,258 |
629,157 |
Venker Eric | President & COO |
Feb 09 '24 |
Sale |
10.92 |
96,950 |
1,058,694 |
532,207 |
Ramaswamy Vivek | 10% Owner |
Jan 02 '24 |
Sale |
11.05 |
3,000,000 |
33,150,000 |
51,929,426 |
Venker Eric | Chief Operating Officer |
Oct 05 '23 |
Sale |
10.11 |
153,027 |
1,547,103 |
595,397 |
Venker Eric | Chief Operating Officer |
Oct 04 '23 |
Option Exercise |
3.85 |
153,027 |
589,154 |
748,424 |
Venker Eric | Chief Operating Officer |
Oct 03 '23 |
Option Exercise |
3.85 |
606,221 |
2,333,951 |
1,201,618 |
Venker Eric | Chief Operating Officer |
Oct 03 '23 |
Sale |
10.25 |
606,221 |
6,213,765 |
595,397 |
Venker Eric | Chief Operating Officer |
Oct 02 '23 |
Option Exercise |
3.85 |
440,752 |
1,696,895 |
1,036,149 |
Roivant Sciences Ltd. | Director |
Oct 02 '23 |
Buy |
38.00 |
1,526,316 |
58,000,008 |
79,805,331 |
Venker Eric | Chief Operating Officer |
Oct 02 '23 |
Sale |
10.80 |
440,752 |
4,760,122 |
595,397 |
Roivant Sciences Ltd Stock (ROIV) Latest News
Where Roivant Sciences Stands With Analysts
Benzinga
The Analyst Landscape: 4 Takes On Roivant Sciences
Benzinga
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
GlobeNewswire Inc.
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Benzinga
Assessing Roivant Sciences: Insights From 5 Financial Analysts
Benzinga
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
GlobeNewswire Inc.
About Roivant Sciences Ltd
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Cap:
|
Volume (24h):